Russell Investments Group
OCUL icon

Russell Investments Group’s Ocular Therapeutix OCUL Stock Holding History

Russell Investments Group’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.29M Buy
152,884
+58,458
+62% +$557K ﹤0.01% 2092
2025
Q4 		$1.15M Buy
94,426
+80,603
+583% +$979K ﹤0.01% 2153
2025
Q3 		$162K Buy
+13,823
New +$165K ﹤0.01% 2872
2025
Q2 		– Sell
-120
Closed -$880 – 3927
2025
Q1 		$880 Buy
120
+52
+76% +$400 ﹤0.01% 3605
2024
Q4 		$581 Hold
68
– – ﹤0.01% 3591
2024
Q3 		$592 Buy
+68
New +$560 ﹤0.01% 3551
2023
Q1 		– Sell
-13,561
Closed -$38.1K – 3353
2022
Q4 		$38.1K Sell
13,561
-17,382
-56% -$57.5K ﹤0.01% 2756
2022
Q3 		$128K Buy
+30,943
New +$156K ﹤0.01% 2630
2021
Q1 		– Sell
-562
Closed -$11K – 3173
2020
Q4 		$11K Buy
+562
New +$8.35K ﹤0.01% 3002

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $4.85B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $57.5B AUM 55.25% 1-Year Est. Return